Battling bullies and other tales by Vertex's new CEO

Matthew Emmens hates golf. For more on the new CEO of Vertex Pharmaceuticals--and ex-chief of Shire--see the Boston Business Journal profile. One tidbit: He's written an allegorical business tale whose moral is, essentially, tell truth to power. He promises to listen at Vertex. Report

Suggested Articles

Post-Tesaro buyout, don’t expect GlaxoSmithKline to spring for more commercial-stage oncology products anytime soon.

Already a fast-growing blockbuster, Novo Nordisk's injectable Ozempic won a major heart-helping FDA nod that could bode well for its oral sibling.

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.